TY  - CHAP
AU  - Steven J. Wolf
AU  - Laurence P.G. Wakelin
AU  - Daniel R. Catchpoole
ED  - Fethi Derbel
Y1  - 2011-11-16
PY  - 2011
T1  - Considerations for Treatment Development in Rhabdomyosarcoma: In Vitro Assessment of Novel DNA Binding Drugs
N2  - Soft tissue tumors include a heterogeneous group of diagnostic entities, most of them benign in nature and behavior. Malignant entities, soft tissue sarcomas, are rare tumors that account for1% of all malignancies. These are predominantly tumors of adults, but 15% arise in children and adolescents. The wide biological diversity of soft tissue tumors, combined with their high incidence and potential morbidity and mortality represent challenges to contemporary researches, both at the level of basic and clinical science. Determining whether a soft tissue mass is benign or malignant is vital for appropriate management. 
This book is the result of collaboration between several authors, experts in their fields; they succeeded in translating the complexity of soft tissue tumors and the diversity in the diagnosis and management of these tumors.
BT  - Soft Tissue Tumors
SP  - Ch. 1
UR  - https://doi.org/10.5772/25387
DO  - 10.5772/25387
SN  - 
PB  - IntechOpen
CY  - Rijeka
Y2  - 2024-04-20
ER  -